| Next 10 |
GERN News and Press, Geron Corporation
-
The following slide deck was published by Geron Corporation in conjunction with their 2022 Q1 earnings call. For further details see: Geron Corporation 2022 Q1 - Results - Earnings Call Presentation
-
Image source: The Motley Fool. Geron (NASDAQ: GERN) Q1 2022 Earnings Call May 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Geron (GERN) Q1 2022 Earnings Call Transcript
-
Geron Corporation. (GERN) Q1 2022 Earnings Conference Call May 09, 2022, 04:30 PM ET Company Participants Aron Feingold - VP of Investor Relations and Corporate Communications Olivia Bloom - Executive VP of Finance and Chief Financial Officer and Treasurer John Scarlett - Chairman and Chief E...
-
Geron press release (NASDAQ:GERN): Q1 GAAP EPS of -$0.09 beats by $0.01. Revenue of $0.12M (-14.3% Y/Y) beats by $0.02M. Under current planning assumptions, the Company projects its existing capital resources, including the net proceeds from the public offering completed in April 2022, and pr...
-
Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Started the Phase 1 IMproveMF Study in Frontline MF in May 2022 Current and Projected Financial Resources Expected to be Sufficient to Reach Planned Miles...
-
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT, CAPL, CARA, CARG, CHMI, CLAR, CLOV, CNNE, CSTL, OTCPK:CURLF, DDD, DHT, DNB, ENTA, EQH, EVBG, FCRD, FF, FGEN, FLL, ...
-
Geron (NASDAQ:GERN) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close. The consensus EPS Estimate is -$0.10 (-11.1% Y/Y) and the consensus Revenue Estimate is $0.1M (-28.6% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downwar...
-
Top line results or TLR from the IMerge phase 3 trial will be out by January 2023. This is a confirmatory trial that may lead to an NDA, if successful. The CEO says he can't wait. Guess what, neither can we. For further details see: Geron: TLR Is 10 Months Away
-
Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2022 financial results after the market closes on Monday, May 9, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a con...
-
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a comp...
Stock Information
MENU
GERN
GERN Quote
GERN Short
GERN News
GERN Articles
Get GERN Alerts
News, Short Squeeze, Breakout and More Instantly...
-
Image source: The Motley Fool. Geron (NASDAQ: GERN) Q1 2022 Earnings Call May 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Geron (GERN) Q1 2022 Earnings Call Transcript
-
Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Started the Phase 1 IMproveMF Study in Frontline MF in May 2022 Current and Projected Financial Resources Expected to be Sufficient to Reach Planned Miles...
-
Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2022 financial results after the market closes on Monday, May 9, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors . Geron will host a con...